
	FORUM Pharmaceuticals Inc. develops life-changing medicines for the treatment of serious brain diseases. Its products include Gamma secretase modulation, an approach to reduce Abeta42 production; HDAC program, an activity of HDAC has an impact on brain diseases that display abnormalities in the gene transcription; PDE 10 program, an investigational phosphodiesterase inhibitor; and alpha-7 Receptor agonists, an orally administered encenicline hydrochloride. The company provides its therapies for Alzheimer&#39;s disease and Schizophrenia. FORUM Pharmaceuticals Inc. was formerly known as EnVivo Pharmaceuticals, Inc. and changed its name to FORUM Pharmaceuticals Inc. in April 2014. The company was founded in 2001 and is based in Watertown, Massachusetts.
